We have recently identified a rare and primitive subpopulation of pulmonary cells that correspond to slow cycling, Oct-4+ expressing cells scattering at bronchoalveolar junctions of lung tissues, and exhibit the characteristics of pulmonary stem/progenitor cells (*PNAS* 103:9530 2006). In addition to Oct-4, these cells also expressed other stem cell markers such as Nanog, SSEA-1, and Sca-1, but not c-Kit, CD34 or p63. Recently, these clonogenic cells have been further purified by selective markers (e.g. CXCR4, ABCG2, *etc*.) and specific culture conditions to promote substantially greater number and size of large colonies. We have also demonstrated that pulmonary stem cells are preferentially infected by SARS-CoV and avian flu virus, H5N1. The infection of stem cells by these newly evolved viruses may lead to loss of capacity for lung repair and serious lung failure. These findings are consistent with the restricted anatomical distribution of the binding receptors in lung preferred by the avian flu viruses. This restriction may account for inefficient transmission of avian flu in mammalian species other than birds. Since virus replicates efficiently in this culture system, it may prove useful for screening new compounds against viral pathogen Our findings indicate that pulmonary stem cells exhibit specific receptors for binding of avian and human flu viruses (Neu5Ac- 2, 3-Gal and Neu5Ac-i2, 6-Gal, respectively). Infection of mice with highly pathogenic H5N1 virus isolate in a P3 facility at the Animal Health Research Institute in Tansui had demonstrated the presence of avian influenza virus at the bronchoalveolar junctions of lung tissues similar to where pulmonary stem cells reside. In glycan microarray, H5N1 reassortant virus, recombinant HA protein and HA-pseudotyped retrovirus bind specifically the sialyl-2,3Gal 1,4NacGlc and sialyl-2, 3Gal, but not the sialyl 2,6Gal or lactose, confirming the binding specificity of HA from H5N1 with cellular receptors. Using the reassortant virus, we have now developed a cell-based assay to evaluate the flu HA-mediated entry, useful for screening and evaluation of HA antagonists and neuraminidase inhibitors. In collaboration with Dr Fang Jim-Min, a new compound, JMF1920, was found to be about 5 times more potent than GS4071 (the active metabolite of Tamiflu) for avian flu viruses.
